Efectividad de la quetiapina como coadyuvante al uso de benzodiacepinas en el trastorno de ansiedad generalizada en pacientes mayores de 20 años de edad durante los años 2017 - 2020 en el HOSNAG.

Abstract

Introduction: Generalized anxiety disorder is a prevalent and disabling mental disorder characterized by excessive anxiety or pathological worry due to a series of events that an individual cannot control, even interrupting their daily activities. Mythology: This is a prevalence, retrospective, crosssectional, descriptive, and analytical study carried out at Hospital Naval de Guayaquil, in patients over 20 years of age who attended with a diagnosis of generalized anxiety disorder who had undergone treatment with quetiapine, benzodiazepines or both during the years 2017-2020. Results: The average age of diagnosis of generalized anxiety disorder is 45.12 years. It prevails in married male patients diagnosed at 39.95 years. Benzodiazepine is the drug that produces clinical improvement in 38% of patients. However, it does not present great variation before quetiapine + benzodiazepine, which produced an improvement in 27% of patients. The treatment time according to the type of drug used is shorter with quetiapine, lasting 4.32 months. According to the Kruskal-Wallis test, the treatment time is shorter with benzodiazepine + quetiapine in a range of 1664.00. The improvement of the sleep disorder stood out with the use of benzodiazepine in 38.57%. Conclusions: The benzodiazepine produces clinical improvement in 38% and in turn improves the sleep disorder in 38.57%. Quetiapine + benzodiazepine provides a shorter treatment time in 1664.00.